2025 marks the 50th anniversary of the Journal of Antimicrobial Chemotherapy, the flagship journal of the British Society for Antimicrobial Chemotherapy. Since March 1975, the journal has published over 19,000 articles from authors around the globe and collated around 1,300 peer-reviewed articles in 188 supplements. To commemorate this occasion, articles will be commissioned on the theme ‘Antimicrobial chemotherapy: past, present and future’ to highlight past achievements, explore current developments, and anticipate the future of antimicrobial chemotherapy.
Latest Published Articles
Background People living with HIV (PLHIV) who fail first-line ART have a higher risk of failing subsequent ART. We examined viral suppression (VS) among adolescents and youths (AY) failing PI ART in Tanzania. Methods We conducted a retrospective study nested within a national third-line cohort of ...
The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality. Rezafungin is a second-generation echinocandin ...
Objectives Eumycetoma is a neglected tropical fungal disease of the subcutaneous tissue that is currently not treatable with medication only. Standard itraconazole therapy is combined with surgical excision of the lesion. Recently, ibrexafungerp, a novel oral antifungal agent inhibiting 1,3-β- D- ...
Background Escherichia coli is the primary aetiological agent of urinary tract infections (UTIs), a frequent cause of antibiotic prescription. Over the years, E. coli has become increasingly resistant towards several antimicrobial drugs used to treat UTIs. Objectives To compare the population ...
Objectives Isavuconazole is efficacious in the treatment of aspergillosis, mucormycosis, and other invasive fungal infections. Therapeutic drug monitoring is generally not assessed during treatment with isavuconazole due to its high oral bioavailability, modest drug–drug interactions, and linear ...
Objectives The benefit of high-dose trimethoprim/sulfamethoxazole (trimethoprim component ≥ 8 mg/kg/day) treatment for Stenotrophomonas maltophilia infections remains unclear. We aimed to evaluate the effect of high-dose trimethoprim/sulfamethoxazole treatment on outcomes in patients with S. ...
Background Antimicrobial resistance among Enterobacter spp. is a significant concern in healthcare settings due to their ability to hyperproduce AmpC β-lactamase, thereby limiting therapeutic options. Cefepime is recommended for treating these infections; however, its efficacy might be compromised ...
Background Recently, we documented that proactive therapeutic drug monitoring (TDM) allowed the successful individualization of the timing of dalbavancin administration in patients requiring prolonged antibiotic treatment. Here, we aimed to identify variables associated with the timing of ...
Background and objectives The treatment of tuberculosis (TB) depends on anti-TB drugs to eradicate the infection and prevent its transmission. Variability in drug metabolism, interactions, and adherence can affect treatment efficacy. Therapeutic drug monitoring (TDM) is essential for optimizing ...
Long-acting injectable (LAI) cabotegravir and rilpivirine have become a convenient alternative to daily oral antiretrovirals, offering monthly or bi-monthly intramuscular injections based on data from clinical trials and real-world evidence. 1–5 However, certain groups, such as transgender ...
Monica Slavin appointed Editor-in-Chief of Journal of Antimicrobial Chemotherapy
The British Society for Antimicrobial Chemotherapy (BSAC) is pleased to announce that Professor Monica Slavin has been appointed as the incoming Editor-in-Chief of BSAC’s flagship journal, Journal of Antimicrobial Chemotherapy. As a recognised leader in the field of fungal infections and infections in immunocompromised hosts, Monica brings a wealth of experience to the role. Her role will officially begin on 1 January 2026.
Read the full announcement
Why publish with JAC?
Explore publishing with the Journal of Antimicrobial Chemotherapy.*
- 14 days to first decision
- 14 days in review
- 18 days from acceptance to advance access publication
*Average manuscript processing times.
Learn more
Recent Supplements
- Future challenges in the management of serious infections
- Syndromic diagnostics: better timing and better insights to deliver improvement to patient experience and outcomes
- European surveillance of antimicrobial consumption: antibiotic consumption in the community, 1997–2017
Open Access Publishing in JAC
The Journal of Antimicrobial Chemotherapy welcomes submissions from authors wishing to submit open access papers.Learn more
Read and Publish deals
Authors interested in publishing in Journal of Antimicrobial Chemotherapy may be able to publish their paper Open Access using funds available through their institution’s agreement with OUP.
Find out if your institution is participating
Meet the Editorial Board
Find out more about Journal of Antimicrobial Chemotherapy’s distinguished Editorial Board, led by Editor-in-Chief Dr J. P. Donnelly.
Learn more
The British Society for Antimicrobial Chemotherapy
The British Society for Antimicrobial Chemotherapy is an inter-professional organisation with over 40 years of experience and achievement in antibiotic education, research and leadership. Dedicated to saving lives through appropriate use and development of antibiotics now and in the future.
Find out more
Altmetrics
Altmetrics
Discover a more complete picture of how readers engage with research in Journal of Antimicrobial Chemotherapy through Altmetric data. Now available on article pages.
Email alerts
Register to receive table of contents email alerts as soon as new issues of Journal of Antimicrobial Chemotherapy are published online.
Sign up
Journal of Antimicrobial Chemotherapy and Web of Science Reviewer Recognition
JAC partners with Web of Science Reviewer Recognition to recognise our expert peer reviewers and raise the status of peer review.
Find out more
ORCID
ORCID® identifiers allow authors and researchers to distinguish themselves, and ensure all their work is always recognised as theirs.
Find out more
Committee on Publication Ethics (COPE)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
publicationethics.org
Recommend to your library
Fill out our simple online form to recommend Journal of Antimicrobial Chemotherapy to your library.
Recommend now
